Author Archives: Craig Primack MD FACP

Recent press as well as a small study or two has hinted that intermittent fasting is metabolically superior to standard dieting and subsequently intermittent fasting has taken off as the current “diet du jour.” In this study by Shubel et al, a randomized controlled trial was performed to test whether intermittent fasting (IF) in a […]

A recent study published in Appetite, shows that when compared to water, artificial sweeteners (low calorie sweeteners) (LCS) do not affect appetite, energy intake or food choices.    For several years, it has been believed commonly (but falsely), that the replacement of sugar by LCS results in several maladaptive physiologic changes including uncoupling of the LCS […]

11

May

PROBIOTICS—Should We Reconsider?

Posted In: Opinion, Research By Craig Primack MD FACP

The use of probiotics has become almost universally recommended.   Two new studies advise caution on the blanket use of probiotics.  Probiotics are beneficial in some patients but other patients may, unfortunately, have little response and even show adverse reactions to probiotics.  To summarize what we know:   Stool samples alone do not provide an accurate picture […]

24

Jan

Obesity Medication Update

Posted In: Pharmacology By Craig Primack MD FACP

Anti-obesity medications are FDA approved for patients who have a BMI over 30 and for patients who have a BMI over 27 if they also have a weight related medical condition, like high blood pressure, high cholesterol, type 2 diabetes mellitus or sleep apnea. I also use medication if a patient has obesity based on body fat percentage, which is generally accepted to be >32% for women and >25% for men. [Read more]

24

Jan

Healthy Moms Raise Healthy Children

Posted In: Research By Craig Primack MD FACP

These are results from a prospective cohort of over 16,000 mom-child pairs followed over the years from childhood to adolescence.
This study found that:
Risk was lower in mom’s who maintained:
A normal BMI, Engaged in at least 150 min/week activities, Did not smoke, Consumed alcohol in Moderation. [Read more]

18

Sep

Vivus Pharmaceuticals announces today that Qsymia is now available for Weight Loss
It is the first available weight loss drug in the last 13 years. The weight loss pill is a combination of 2 existing drugs: Phentermine and topiramate. It will be a good tool for weight loss in addition to a plan that includes dietary change, exercise and behavior modification. [Read more]

The new drug, Qsymia, (Vivus) has just been approved by the FDA for Weight Loss and Obesity Treatment. Qsymia is a combination of phentermine and extended release topiramate. The name that has been proposed for the last few years for this drug, Qnexa, has just been changed to Qsymia. [Read more]